Houlihan Lokey Advises Nomi Health on Its Sale of CerpassRx

Houlihan Lokey is pleased to announce that CerpassRx, a division of Nomi Health, has agreed to be acquired by LucyRx, a portfolio company of Summit Partners.

The combination brings together CerpassRx’s proven track record of exceptional service and cost containment with LucyRx’s technology-driven clinical approach, all under a shared vision for smarter, more transparent prescription care. By combining LucyRx’s technology-driven clinical model with CerpassRx’s service-first approach and cost containment expertise, this partnership creates a more impactful pharmacy benefit manager (PBM) solution—one that delivers smarter care, stronger savings, and a seamless experience for clients and members alike.

CerpassRx is a leading, full-service pharmacy benefit manager based in Dallas-Fort Worth, Texas. Its services include prescription optimization, flexible formulary designs, personalized member support, and efficient mail and specialty pharmacy programs. Committed to driving efficiency and enhancing pharmacy benefit management, CerpassRx helps clients navigate the complexities of prescription care.

Nomi Health is rebuilding healthcare through its direct model. Founded in 2019, the company’s integrated platform combines analytics, direct provider networks, and real-time payment solutions—providing the infrastructure that powers better healthcare. The company serves 4,000 customers nationwide, impacting 30 million lives and influencing more than $200 billion in healthcare spend. Based in Orem, Utah, Nomi Health leads the movement to rebuild America’s healthcare system.

LucyRx is a fast-scaling, independent, next-generation PBM redefining prescription care. Fueled by innovation and decades of leadership experience, LucyRx delivers better outcomes through its integrated specialty network, formulary marketplace, and next-day home delivery solutions. Powered by its proprietary AI platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves over 1,200 clients nationwide.

Houlihan Lokey served as the exclusive sellside advisor to Nomi Health and CerpassRx. This transaction illustrates our Healthcare Group’s leadership position in employer-sponsored healthcare and represents the 12th transaction we have advised on in the past 12 months, comprising more than $4.5 billion in aggregate enterprise value.

RELATED: Pharma Services, Mergers & Acquisitions